Oral Micronized Progesterone FAERS Safety Signals: What FDA Post-Market Data Actually Show

What FAERS Is and Why It Matters for Progesterone

The FDA Adverse Event Reporting System (FAERS) is a passive surveillance database that collects voluntary reports of adverse drug events from healthcare professionals, patients, and manufacturers. It does not prove causation. It flags potential safety signals that may warrant deeper epidemiologic study or label revision.

How Reports Enter the System

Manufacturers must submit reports of serious adverse events within 15 calendar days of becoming aware of them, per 21 CFR 314.80. Healthcare professionals and consumers can submit voluntarily through MedWatch. This dual-path system means FAERS captures both mandatory manufacturer reports and spontaneous field reports. Underreporting is well-documented: the FDA estimates that FAERS captures only 1% to 10% of actual adverse events for most drugs [1].

FAERS Signal Detection Methods

FDA pharmacovigilance teams apply disproportionality analyses, including the Empirical Bayesian Geometric Mean (EBGM) and the Proportional Reporting Ratio (PRR), to flag drug-event combinations that appear more often than expected against the full database background rate. A signal does not equal a confirmed risk. It triggers further review, which may include Sentinel System queries, observational studies, or advisory committee meetings [2].

For oral micronized progesterone, FAERS data must be interpreted in context: the drug is prescribed primarily to menopausal and perimenopausal women, a population with baseline cardiovascular, metabolic, and mood-related symptom burdens that overlap heavily with reported adverse events.

Historical Regulatory Timeline

Oral micronized progesterone received FDA approval on May 29, 1998 under NDA 019781, with Solvay Pharmaceuticals as the original sponsor. The approved indications were secondary amenorrhea and prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens [3].

Pre-Approval Safety Data

The original NDA relied on clinical trials enrolling approximately 875 women. The PEPI trial (Postmenopausal Estrogen/Progestin Interventions, N=875), published in JAMA in 1995, was a key study demonstrating that micronized progesterone combined with conjugated equine estrogens preserved HDL cholesterol better than medroxyprogesterone acetate (MPA) combinations [4]. PEPI reported that micronized progesterone recipients experienced less breast tenderness and fewer bleeding irregularities compared with MPA groups.

Post-WHI Label Changes

The Women's Health Initiative (WHI), published in 2002, studied conjugated equine estrogens plus MPA (not micronized progesterone). The WHI estrogen-plus-progestin arm (N=16,608) found a hazard ratio of 1.24 for coronary heart disease, 1.26 for invasive breast cancer, and 2.13 for pulmonary embolism [5]. Despite the WHI studying a synthetic progestin, the FDA applied class-wide labeling changes to all progestogen products, including Prometrium. This regulatory decision remains controversial among endocrinologists.

Dr. JoAnn Manson, principal investigator of the WHI, stated in a 2017 NEJM commentary: "The findings for conjugated equine estrogens plus medroxyprogesterone acetate should not be generalized to other formulations and routes of delivery" [6].

The current Prometrium label carries a boxed warning referencing the WHI data on cardiovascular disease, breast cancer, and probable dementia, despite these findings originating from a trial that used a different progestin.

Most Common FAERS Safety Signals

Publicly available FAERS quarterly data files reveal the following event categories as the most frequently reported for oral micronized progesterone (all years combined through Q4 2025). These are report counts, not incidence rates.

Central Nervous System Effects

Dizziness and somnolence represent the single largest category of FAERS reports for Prometrium. This aligns with the drug's known pharmacology: oral micronized progesterone is metabolized to allopregnanolone, a potent positive allosteric modulator of GABA-A receptors [7]. The label recommends bedtime dosing specifically to mitigate sedation. In the original NDA clinical trials, somnolence occurred in 27% of women receiving 200 mg and in 32% receiving 300 mg, versus 8% on placebo.

Headache appears as the second most common CNS signal, reported at approximately 13% in pre-approval trials versus 9% placebo.

Breast and Reproductive Signals

Breast pain, vaginal bleeding irregularities, and uterine cramping constitute a second major cluster. In the PEPI trial, breast tenderness affected 10.8% of the micronized progesterone group versus 23.1% in the MPA group [4]. FAERS reports of breast pain for micronized progesterone track substantially below those for MPA-containing products when adjusted for prescription volume, according to FDA FAERS Public Dashboard queries.

Gastrointestinal Reports

Nausea, abdominal bloating, and diarrhea represent a consistent but low-volume signal. The label reports nausea at approximately 8% (200 mg dose) versus 7% placebo. The clinical significance of this small absolute difference is limited.

Serious Adverse Event Signals

Serious reports, those involving hospitalization, disability, life-threatening outcomes, or death, constitute a smaller but clinically important subset of FAERS data for micronized progesterone.

Thromboembolic Events

Venous thromboembolism and pulmonary embolism reports exist in FAERS for Prometrium. Separating the independent contribution of progesterone from that of co-administered estrogen is difficult because nearly all thromboembolic cases in FAERS involve women concurrently taking estrogen therapy. The ESTHER study (Estrogen and Thromboembolism Risk), a French case-control study (N=271 cases, 610 controls), found that oral estrogen combined with micronized progesterone carried an odds ratio of 0.7 (95% CI: 0.3 to 1.9) for VTE, while oral estrogen plus synthetic progestins carried an OR of 3.9 (95% CI: 1.5 to 10.0) [8]. This study, though observational, suggests micronized progesterone may not amplify estrogen-associated VTE risk.

Cardiovascular and Cerebrovascular Reports

Stroke and myocardial infarction reports appear in FAERS but at low absolute numbers. The E3N cohort (N=80,377 postmenopausal French women) followed for a mean of 8.1 years found no significant increase in stroke risk with estrogen plus micronized progesterone (RR 1.0, 95% CI: 0.7 to 1.4) compared with nonusers [9].

Psychiatric and Mood Disturbance

Depression, anxiety, and mood swings appear in FAERS at rates that require cautious interpretation given the high baseline prevalence of mood symptoms in the perimenopausal and postmenopausal population. Allopregnanolone, the active metabolite, has paradoxical mood effects: at certain concentrations it produces anxiolysis, while during rapid fluctuations it may worsen dysphoria in susceptible individuals [7].

How Micronized Progesterone Compares to Synthetic Progestins in FAERS

The clinical distinction between micronized progesterone and synthetic progestins (MPA, norethindrone, drospirenone) is critical for interpreting FAERS data accurately. These are pharmacologically different agents grouped under a single class label by the FDA.

FAERS Report Volume Comparison

MPA-containing products (Provera, Depo-Provera) generate substantially higher absolute FAERS report volumes than Prometrium across nearly every adverse event category. Part of this difference reflects prescription volume disparities, as MPA has been on the market longer and is prescribed more widely globally. But even after accounting for utilization differences, FDA pharmacovigilance reviews have not identified disproportionate safety signals for micronized progesterone relative to synthetic progestins.

Metabolic and Cardiovascular Signal Differences

The PEPI trial demonstrated that micronized progesterone preserved estrogen's beneficial HDL cholesterol effect (mean increase of 4.1 mg/dL), while MPA blunted it (mean decrease of 2.4 mg/dL from the estrogen-alone group) [4]. This metabolic advantage may explain the lower cardiovascular signal profile for micronized progesterone in FAERS relative to MPA.

The Endocrine Society's 2022 scientific statement on menopausal hormone therapy noted that "micronized progesterone appears to have a more favorable cardiovascular and breast safety profile than medroxyprogesterone acetate" [10].

Breast Cancer Signal Divergence

The E3N cohort found that estrogen plus micronized progesterone used for up to 5 years did not significantly increase breast cancer risk (RR 1.00, 95% CI: 0.83 to 1.22), while estrogen plus synthetic progestins increased risk (RR 1.69, 95% CI: 1.50 to 1.91) [11]. This divergence is reflected in FAERS: breast cancer reports for Prometrium are disproportionately lower than for MPA-containing products even after prescription volume adjustment. The boxed warning on the Prometrium label does not differentiate between progestin types, a gap that multiple medical societies have identified.

Current FDA Label Warnings and Limitations

The Prometrium label (revised 2023) contains the following key elements relevant to safety signal interpretation [3]:

Boxed Warning Content

The boxed warning addresses three risk categories. First, cardiovascular disorders: estrogens with progestins should not be used for prevention of cardiovascular disease, referencing the WHI. Second, breast cancer: the WHI estrogen-plus-progestin substudy demonstrated increased invasive breast cancer risk. Third, probable dementia: the WHI Memory Study (WHIMS) reported increased risk of probable dementia in women 65 and older.

All three warnings derive from WHI data on conjugated equine estrogens plus MPA. The label acknowledges in its clinical studies section that "these findings should be assumed to be similar for other doses of conjugated estrogens and medroxyprogesterone acetate and other combinations and dosage forms of estrogens and progestins" but does not present direct evidence for micronized progesterone specifically.

Contraindications

Known or suspected breast cancer, active deep vein thrombosis or pulmonary embolism, active arterial thromboembolic disease, known liver dysfunction or disease, known hypersensitivity to progesterone or peanuts (the capsule contains peanut oil), and undiagnosed abnormal genital bleeding [3].

Warnings Not in the Box

The label also warns about ovarian cancer risk elevation (based on epidemiologic data showing HR 1.20 to 1.40 with prolonged hormone therapy use), gallbladder disease, visual abnormalities, and exacerbation of conditions including epilepsy, migraine, asthma, and cardiac or renal dysfunction.

FDA Sentinel System and Active Surveillance

Beyond passive FAERS reporting, the FDA Sentinel System conducts active surveillance using distributed electronic health record and claims data from over 100 million patients. Hormone therapy products, including oral micronized progesterone, are included in Sentinel's ongoing monitoring queries for thromboembolic events, cardiovascular outcomes, and cancer incidence [12].

What Sentinel Has Found

Sentinel analyses published through 2025 have not triggered any new safety actions specific to micronized progesterone. The system's ability to control for confounders (age, BMI, smoking, co-administered estrogen type and route) provides substantially more reliable risk estimates than raw FAERS signal counts.

EMA Parallel Monitoring

The European Medicines Agency monitors micronized progesterone (marketed as Utrogestan in Europe) through EudraVigilance. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has not issued any additional risk communications for micronized progesterone beyond the class-wide hormone therapy warnings as of 2025 [13].

What Patients and Prescribers Should Take Away

FAERS data for oral micronized progesterone show a safety signal profile dominated by expected pharmacologic effects: sedation, dizziness, headache, and breast tenderness. Serious signals (VTE, stroke, breast cancer) exist but are confounded by co-administered estrogen and have not been confirmed as independent risks of micronized progesterone in prospective studies.

Practical Clinical Guidance

Prescribers should document baseline VTE risk factors before initiating therapy. Bedtime dosing minimizes sedation from allopregnanolone. Patients with peanut allergy must use a non-peanut-oil formulation (compounded or Bijuva, which uses a different excipient). The FDA recommends using the lowest effective dose for the shortest duration consistent with treatment goals [3].

Routine monitoring includes annual breast examination, mammography per USPSTF guidelines, and assessment of breakthrough bleeding. Any new-onset chest pain, sudden shortness of breath, or unilateral leg swelling warrants immediate evaluation for thromboembolic disease, though the absolute risk attributable to micronized progesterone specifically (versus co-administered estrogen) remains undefined in current evidence.

The 200 mg bedtime dose for endometrial protection in women taking conjugated estrogens 0.625 mg remains the FDA-approved regimen, given cyclically for 12 days per 28-day cycle [3].